[Click eStock] "Appclon, Expected to Overcome High Relapse Rate Drawbacks of CAR-T... Candidate for the Second HLB"

Stunning Value Research forecasted on the 8th that Appclon is the top candidate for the second HLB. No investment opinion or target price was provided.

Appclon is an anti-cancer antibody specialized new drug development company developing monoclonal antibodies, bispecific antibodies, and CAR-T therapeutics based on its proprietary platform NEST.

The main pipelines include AC101 (monoclonal antibody), an antibody therapeutic targeting disease protein HER2 for indications such as gastric and breast cancer; AT101, a CAR-T cell therapy targeting disease protein CD19 for hematologic cancers developed on the CAR-T platform; and AT501, targeting disease protein HER2 and under development for solid tumors.

Namgung Jun, a researcher at Stunning Value Research, said, "The CAR-T therapeutic AT101 is currently undergoing a Phase 2 clinical trial in Korea," adding, "While major CD19 protein-targeting CAR-T therapies currently on the market, such as Kymriah and Yescarta, all use the same antibody, Appclon is developing a new h1218 antibody and epitope."

He explained, "In terms of efficacy, it is superior to Kymriah and Yescarta, and patients who participated in Appclon's Phase 1 CAR-T clinical trial have not relapsed for several dozen months, which is encouraging."

In particular, Stunning Value evaluated Appclon as the second HLB candidate. He emphasized, "The interim results of AT101's Phase 2 clinical trial are expected to be announced between October and November," adding, "It has superior efficacy compared to the best chimeric antigen receptor T-cell (CAR-T) therapies, and higher patient survival rates than Yescarta, so it is currently pursuing accelerated approval with high expectations."

He stated, "There is a very high possibility that it will become the second HLB, similar to HLB, a targeted anticancer drug company targeting vascular endothelial growth factor receptor 2 (VEGFR-2)."